Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 4Dermatologic 4Gynecologic 3Thoracic 2Genitourinary 2Sarcoma 1Head & Neck 1CNS 1

Conditions

Ovarian Neoplasms 2Neoplasm Metastasis 2Melanoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Glioblastoma 1Fibrolamellar hepatocellular carcinoma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Brain Neoplasms 1Astrocytoma 1Adenoma, Islet Cell 1

Interventions

Paclitaxel 140pembrolizumab 119Carboplatin 104Bevacizumab 90Cisplatin 67Specimen Handling 62Magnetic Resonance Spectroscopy 51olaparib 50Gemcitabine 39Nivolumab 36Biopsy 36liposomal doxorubicin 32Taxes 31Cyclophosphamide 31Blood Specimen Collection 29niraparib 27lenvatinib 26Letrozole 26Doxorubicin 26Topotecan 25Drug Therapy 25Immunoglobulin G 22fludarabine 21atezolizumab 21Radiotherapy 21Brachytherapy 21Disulfides 20durvalumab 19Surveys and Questionnaires 19dostarlimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
aflibercept × Gynecologic × 1 year × Clear all
NCT02298959 2026-05-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
59 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT02159989 2025-10-20

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Completed
83 enrolled 21 charts
GastrointestinalGynecologic

Fibrolamellar hepatocellular carcinoma, Adenoma, Islet Cell, Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡